The German biotechnology firm BioNTech, a name synonymous with the rapid development of the world’s first widely authorized mRNA COVID-19…
Read More
BioNTech’s Dramatic Pivot: From €19B COVID Vaccine Fortunes to 1,860 Job Cuts and a €16.8B Oncology Bet
The German biotechnology powerhouse BioNTech, once synonymous with its groundbreaking COVID-19 vaccine Comirnaty, is undergoing a profound strategic transformation, shedding…
Read More
BioNTech’s Dramatic Pivot: From Pandemic Powerhouse to Oncology Challenger Amidst Job Cuts and Shifting Fortunes
The German biotechnology firm BioNTech, once a beacon of innovation and a financial titan thanks to its pioneering mRNA COVID-19…
Read More
Cellular Intelligence Licenses Novo Nordisk’s Parkinson’s Cell Therapy Program Following Company’s Strategic Pivot
Seven months after Danish pharmaceutical giant Novo Nordisk officially shuttered its dedicated cell therapy unit in October 2025, a significant…
Read More
MSD’s $6.7 Billion Acquisition of Terns Pharmaceuticals Signals a Bold Strategic Pivot in Oncology to Secure Future Growth
On March 25, Merck & Co. (MSD) announced a significant strategic move, acquiring Terns Pharmaceuticals for an estimated $6.7 billion…
Read MoreYOU MAY HAVE MISSED
